[go: up one dir, main page]

UY27696A1 - Compuestos que modulan la actividad de ppar - Google Patents

Compuestos que modulan la actividad de ppar

Info

Publication number
UY27696A1
UY27696A1 UY27696A UY27696A UY27696A1 UY 27696 A1 UY27696 A1 UY 27696A1 UY 27696 A UY27696 A UY 27696A UY 27696 A UY27696 A UY 27696A UY 27696 A1 UY27696 A1 UY 27696A1
Authority
UY
Uruguay
Prior art keywords
compounds
ppar
activity
modulate
describes
Prior art date
Application number
UY27696A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary F Filzen
Andrew G Geyer
Chitase Lee
Bharat K Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27696A1 publication Critical patent/UY27696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención describe compuestos que alteran la actividad de PPAR. La invención también describe sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos a sus sales, y métodos para utilizarlas como agentes terapéuticos para tratar o prevenir hiperlipidemia e hipercolesteremia en un mamífero. La presente invención también describe un método para obtener los compuestos descritos.
UY27696A 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar UY27696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36241102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
UY27696A1 true UY27696A1 (es) 2003-10-31

Family

ID=27789158

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27696A UY27696A1 (es) 2002-03-07 2003-03-06 Compuestos que modulan la actividad de ppar

Country Status (15)

Country Link
US (3) US6867224B2 (es)
EP (1) EP1480641A1 (es)
JP (1) JP2005527509A (es)
AR (1) AR038882A1 (es)
AU (1) AU2003207914A1 (es)
BR (1) BR0308202A (es)
CA (1) CA2478164A1 (es)
GT (1) GT200300054A (es)
MX (1) MXPA04008627A (es)
NI (1) NI200300039A (es)
PA (1) PA8568601A1 (es)
PE (1) PE20040190A1 (es)
TW (1) TW200405812A (es)
UY (1) UY27696A1 (es)
WO (1) WO2003074051A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002335231B2 (en) * 2001-10-12 2008-05-08 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor delta
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
JP2006514069A (ja) * 2003-01-06 2006-04-27 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子としての融合複素環式誘導体
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
AU2004255580B2 (en) 2003-07-02 2009-10-08 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MXPA06004642A (es) * 2003-11-05 2006-06-27 Hoffmann La Roche Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar).
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
KR100802864B1 (ko) * 2004-03-09 2008-02-12 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 피라졸릴 인돌릴 유도체
ATE410422T1 (de) * 2004-03-09 2008-10-15 Hoffmann La Roche Pyrazolylindolylderivate als ppar-aktivatoren
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
AU2005305593A1 (en) * 2004-11-18 2006-05-26 Pfizer Products Inc. Drugs and prodrugs useful for the treatment of energy balance in ruminants
KR101377790B1 (ko) * 2005-02-25 2014-03-27 오노 야꾸힝 고교 가부시키가이샤 인돌 화합물 및 이의 용도
CA2613365C (en) 2005-06-30 2013-08-13 Novo-Nordisk A/S Phenoxy acetic acids as ppar delta activators
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8202686B2 (en) * 2007-03-22 2012-06-19 Advanced Liquid Logic, Inc. Enzyme assays for a droplet actuator
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
EP2516669B1 (en) 2009-12-21 2016-10-12 Advanced Liquid Logic, Inc. Enzyme assays on a droplet actuator
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
JP5257490B2 (ja) 2010-06-21 2013-08-07 小野薬品工業株式会社 ４，４’−［４−フルオロ−７−（｛４−［４−（３−フルオロ−２−メチルフェニル）ブトキシ］フェニル｝エチニル）−２−メチル−１ｈ−インドール−１，３−ジイル］ジブタン酸、４，４’−［２−メチル−７−（｛４−［４−（ペンタフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸および４，４’−［４−フルオロ−２−メチル−７−（｛４−［４−（２，３，４，６−テトラフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸の新規結晶形
US9513253B2 (en) 2011-07-11 2016-12-06 Advanced Liquid Logic, Inc. Droplet actuators and techniques for droplet-based enzymatic assays
CN104254525B (zh) * 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
WO2001094335A2 (en) 2000-06-02 2001-12-13 Eli Lilly & Company Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
WO2001092250A2 (en) 2000-06-02 2001-12-06 Cor Therapeutics, Inc. Synthesis of 2-acyl substituted chromanes and intermediates thereof
AU2001284659A1 (en) 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
WO2002096904A1 (en) 2001-05-29 2002-12-05 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
HRP20031002A2 (en) 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US6924295B2 (en) 2001-06-18 2005-08-02 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
US20050107442A1 (en) 2005-05-19
MXPA04008627A (es) 2004-12-06
BR0308202A (pt) 2004-12-21
NI200300039A (es) 2005-09-21
CA2478164A1 (en) 2003-09-12
PA8568601A1 (es) 2003-11-12
EP1480641A1 (en) 2004-12-01
US20050113422A1 (en) 2005-05-26
US6867224B2 (en) 2005-03-15
AU2003207914A1 (en) 2003-09-16
JP2005527509A (ja) 2005-09-15
TW200405812A (en) 2004-04-16
US7109222B2 (en) 2006-09-19
US20030207915A1 (en) 2003-11-06
WO2003074051A1 (en) 2003-09-12
GT200300054A (es) 2003-10-10
AR038882A1 (es) 2005-02-02
PE20040190A1 (es) 2004-03-20

Similar Documents

Publication Publication Date Title
UY27704A1 (es) Compuestos que modulan la actividad de ppar
UY27696A1 (es) Compuestos que modulan la actividad de ppar
ECSP045285A (es) Compuestos que modulan la actividad de ppar
DOP2003000620A (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparación
DOP2004000881A (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
UY39188A (es) Imidazopiridazinas como moduladores de il-17
CR8926A (es) Acidos de tiazolo-naftilo
MX382184B (es) Cisteamina recubierta entericamente, cistamina y derivados de ellas.
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
ECSP088352A (es) Derivados de indol 1,3-disustituido para su uso como moduladores de ppar
PA8680701A1 (es) Derivados de oxindol
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
BRMU8400812Y1 (pt) aperfeiçoamento introduzido em fonte de luz para tratamento da hiperbilirrubinemia por fototerapia.
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
CR9903A (es) Compuestos antihipercolesterolemicos
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
ECSP067008A (es) Compuestos de opioide carboxamido

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126